October, 2025
October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
Oct 17, 2025, 09:00

Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA

Shreya Agarwal, Assistant Professor of Pediatric Hematology at UCSF Benioff Children’s Hospitals, reposted from RPTH Journal on LinkedIn:

”Grateful to RPTH for highlighting our recent study on Plasminogen (PLG) mutation- associated thrombotic microangiopathy (TMA).

In this work, we describe patients with PLG mutations who experienced recurrent TMA despite complement blockade therapy, and raises suspicion if there is an alternate disease pathway worth exploring.

We are now hoping to assess the feasibility of a multicenter study to better understand PLG mutations-associated TMA.

If you’ve cared for patients with plasminogen mutations and TMA, we’d be grateful if you could take a few minutes to complete our short survey.

Thank you to my amazing coauthors Nicola Pozzi, Senthil Sukumar, Camila Masias MD, Anuja Java and Spero Cataland for their collaboration on this project!”

Quoting RPTH Journal‘s post:

”Not all thrombotic microangiopathies (TMAs) behave the same, and they don’t all respond to complement blockade.

In a new study, Shreya Agarwal, MD and team describe a subset of patients with plasminogen (PLG) mutations who experienced recurrent TMA despite standard therapy.

Their response to anticoagulation hints at an alternative disease pathway worth exploring.

Coauthors: Nicola Pozzi; Senthil Sukumar, Camila Masias MD, Spero Cataland’

Read the full article in RPTH.

Article: Plasminogen mutation–associated thrombotic microangiopathy and role of anticoagulation: a single institution case series

Authors: Shreya Agarwal, Nicola Pozzi, Senthil Sukumar, Camila Masias, Anuja Java, Spero Cataland

Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.